WPD Pharmaceuticals to Conduct Clinical Trials in Pediatric Brain Tumors Through Collaboration With CNS Pharmaceuticals
February 12 2020 - 3:05AM
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the
“
Company” or “
WPD”), a clinical
stage pharmaceutical company, is pleased to announce its plan to
initiate a Phase I clinical trial for Berubicin in pediatric brain
cancer in Poland in collaboration with CNS Pharmaceuticals, Inc.
(NASDAQ: CNSP) (“
CNS”), a biotechnology company
specializing in the development of novel treatments for primary and
metastatic brain and central nervous system tumors.
The Company, in collaboration with CNS, is
planning to conduct the upcoming Phase I clinical trial at
Children’s Memorial Health Institute (“Children’s
Memorial”), the largest pediatric hospital in
Poland. The Company believes this Phase
I trial of Berubicin at Children’s
Memorial represents the
first ever investigation of an anthracycline
and topoisomerase II inhibitor in pediatric brain
tumors. WPD and CNS are currently working
with experts at Children’s
Memorial to complete documentation for the
upcoming study and scientific advice meeting.
As previously announced, WPD and CNS entered
into a sublicense agreement which granted WPD commercial rights in
a limited territory to Berubicin, including research and
development. Subsequently, WPD was awarded a $6 million grant from
the EU/Polish National Center for Research and Development. WPD
plans to utilize funds from the grant to fund the upcoming Phase I
trial and has the full support from CNS to execute these
studies.
Mariusz Olejniczak, CEO of WPD
Pharmaceuticals, commented, “We are very excited to
initiate a Phase I clinical trial and further expand the scope of
Berubicin. We look forward our collaboration with CNS and
Children’s Memorial in Poland to initiate what we believe to be the
first investigation of a unique topoisomerase II inhibitor that
appears to be able to cross the blood-brain barrier in pediatric
brain tumors. We will continue to drive the clinical
development of Berubicin in the upcoming Phase II trial in adult
patients.”
About Berubicin
Berubicin is an anthracycline, a class of
anticancer agents that are among the most powerful chemotherapy
drugs and effective against more types of cancer than any other
class of chemotherapeutic agents. Anthracyclines are designed to
utilize natural processes to induce deoxyribonucleic acid (DNA)
damage in targeted cancer cells by interfering with the action of
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin treatment of brain cancer patients appeared to
demonstrate positive responses that include one durable complete
response in a Phase 1 human clinical trial conducted by Reata.
About WPD Pharmaceuticals
WPD is a biotechnology research and development
company with a focus on oncology, namely research and development
of medicinal products involving biological compounds and small
molecules. WPD has 10 novel drug candidates with 4 that are
in clinical development stage. These drug candidates were
researched at institutions including MD Anderson Cancer Center,
Mayo Clinic and Emory University, and WPD currently has ongoing
collaborations with Wake Forest University and leading hospitals
and academic centers in Poland.
WPD has entered into license agreements with
Wake Forest University Health Sciences and sublicense agreements
with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc.,
respectively, each of which grant WPD an exclusive, royalty-bearing
sublicense to certain technologies of the licensor. Such agreements
provide WPD with certain research, development, manufacturing and
sales rights, among other things.
On Behalf of the Board
‘Mariusz Olejniczak’
Mariusz OlejniczakCEO, WDP Pharmaceuticals
Contact:
Investor RelationsEmail: investors@wpdpharmaceuticals.comTel:
604-428-7050Web: www.wpdpharmaceuticals.com
Cautionary Statements:
Neither the Canadian Securities Exchange nor the
Investment Industry Regulatory Organization of Canada accepts
responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking
statements. Forward-looking statements are statements that
contemplate activities, events or developments that the Company
anticipates will or may occur in the future. Forward-looking
statements in this press release include that we will conduct Phase
I clinical trial at Children’s Memorial pediatric hospital in
collaboration with CNS; that clinical development of
Berubicin will continue in the upcoming Phase II trial in adult
patients and that WPD’s drugs could be developed into novel
treatments for cancer. These forward-looking statements reflect the
Company’s current expectations based on information currently
available to management and are subject to a number of risks and
uncertainties that may cause outcomes to differ materially from
those projected. Factors which may prevent the forward
looking statement from being realized is that the plans to complete
Phase I or Phase II clinical trials are disrupted; that Phase II
does not occur because of a failure during Phase I; that
competitors or others may successfully challenge a granted patent
and the patent could be rendered void; that we are unable to raise
sufficient funding for our research; that our drugs don’t provide
positive treatment, or if they do, the side effects are damaging;
competitors may develop better or cheaper drugs; and we may be
unable to obtain regulatory approval for any drugs we develop.
Readers should refer to the risk disclosure included from
time-to-time in the documents the Company files on SEDAR, available
at www.sedar.com. Although the Company believes that the
assumptions inherent in these forward-looking statements are
reasonable, they are not guarantees of future performance and,
accordingly, they should not be relied upon and there can be no
assurance that any of them will prove to be accurate.
Finally, these forward-looking statements are made as of the date
of this press release and the Company assumes no obligation to
update them except as required by applicable law.
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Jul 2024 to Aug 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Aug 2023 to Aug 2024